Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
|Articles|August 27, 2020
Neurotrophic keratopathy and ocular surface disease
Advertisement
Ahmad Fahmy, OD, FAAO, explains that the line in the sand for the ocular surface is the corneal epithelium. He outlines his talk at Dry Eye Everything Virtual Symposium which looks at how corneal nerve sensation intersects with the health of the ocular surface.
Advertisement
Related to this article
Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
Missed AAOpt 2026? Here are the highlights by specialty
4
FDA approves subcutaneous Enspryng for TED
5